The utility of aprindine blood levels in the management of ventricular arrhythmias.
Sixty-four patients with a history of ventricular tachycardia and ventricular fibrillation refractory to conventional therapy received aprindine to abolish recurrent episodes of symptomatic ventricular tachycardia. Fifty-six patients became asymptomatic and were followed up for a mean period of 23 months. Aprindine dose was adjusted to minimize adverse reactions but still control arrhythmia. Survival analysis was performed for the group with aprindine levels greater than 1.5 micrograms/ml and the group with levels of 1.5 micrograms/ml or less. At the end of the study, 65% of the patients with a high level were alive and asymptomatic as compared with only 35% of the patients with a low level (p less than 0.036). In patients at risk of recurrent sudden cardiac death, high aprindine levels maintained after abolition of symptomatic ventricular tachycardia were associated with improved survival.
D001073:Aprindine / Q000097:blood* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007192:Indenes / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013575:Syncope / Q000503:physiopathology; D013610:Tachycardia / Q000188:drug therapy* / Q000401:mortality; D013997:Time Factors; D014693:Ventricular Fibrillation / Q000188:drug therapy* / Q000401:mortality
D007192:Indenes; D001073:Aprindine